Glad

Davanrik was developed to treat depression. However it was later found tabu that it also affected the hunger of the person and could be utilization as a do medicates for obesity patients. Davanrik was currently in the pre-clinical development stage when it was offered to Merck to licence it. Since research laboratory was a subaltern company could not afford to get it done the FDA citation process. LAB offered to give the rights to Merck if pay it an initial all(a)owance rundown payment on each stage and scud the drug through the entire FDA approval stage, manufacture the drug, commercialize the drug and pay a royalty on all gross revenue to LAB. Clinical Approval Stages In kind 1, the drug would be administered to 20-80 healthy volunteers to test for safety. The stage would develop 2 years. If Merck opinionated to go ahead with the first arrange investment, it would cost $30 jillion including an initial $5 gazillion fee to LAB for licensing the drug. Probabili ty of success of signifier 1 is 60%.

In Phase 2, a larger number (100-300) of patient volunteers argon tested to determine if the drug is effective or not. Does the recitation of drug have any side do on patients. It was estimated that there is only 10% prospect that Phase 2 would show that Davanrik would be effective for depression only, 15% probability for weight loss only, and a 5% probability for both(prenominal) depression and weight loss. This phase would also require 2 years and would cost $40 million including a $2.5 million licensing milestone payment to LAB.If you want to get a swarm essay, order it on our website: OrderCustomPaper.com

If you want to get a full essay, visit our page: write my paper